Q4 2022 Donaldson Company Inc Earnings Call
Good morning, ladies and gentlemen, thank you for standing by welcome to Donaldson company's fourth quarter and full year 2022 earnings conference call.
At this time all participants are in a listen only mode. After the speaker's presentation there'll be a question and answer session.
Ask a question you will need to press star followed by the number one on your telephone keypad.
If you require operator assistance at any time, Please press star zero.
I would now like to turn the call over to <unk> director of Investor Relations. Please go ahead.
Good morning, Thank you for joining donaldson's fourth quarter and full year fiscal 2022 earnings conference call with me today are Tod Carpenter, Chairman, CEO, and President and Scott Robinson, Chief Financial Officer. This morning, Tod and Scott will provide a summary of our.
Fourth quarter performance and details on our outlook for fiscal 2023.
New and beginning this quarter. We are also providing investors with the supplemental quarterly earnings presentation summarizing our results and outlook, which can be found on our investor relations website at IR Dot Donaldson dotcom.
As a reminder, during today's call we will reference non-GAAP metrics, a reconciliation of GAAP to non-GAAP metrics is provided within the schedules attached to this morning's press release. Additionally, please keep in mind that any forward looking statements made during this call are subject to risks and uncertainties, which are described in our pea.
Press release, and SEC filings with that I'll now turn the call over to Tod Carpenter. Please go ahead.
Thanks, <unk>. Good morning, everyone fiscal 2022 was a challenging year, given the macroeconomic and geopolitical environment.
Im really proud of the way our team rallied together in support of our mission of advancing filtration for a cleaner world.
We ended the year with revenue over $3 billion, including a $1 billion contribution from our industrial business.
Adjusted earnings per share were $2 68.
In line with our most recent guidance, we also returned $281 million to shareholders in the form of dividends and share buybacks.
We lived up to our principle of enriching our communities throughout the year and gave back for example, donating to the relief efforts in eastern Europe, and delivering meals to our employees in Shanghai. During the recent COVID-19, Lockdowns. We also achieved our fiscal 2022 ESG goal of reducing our cotwo.
Emissions by 6000 metric tons, representing a 5% reduction from the 2019 baseline.
We invested for our future across several areas.
And our customers through our research and development and capacity expansions and our long term profitable growth through our advance and accelerate portfolio, including acquisitions, particularly in the life sciences sector and in our team, including the addition of new leadership positions supporting <unk>.
G and diversity equity and inclusion.
Now on the fourth quarter, we closed the year strong sales were up 15% with a pricing contribution of 12% and the negative impact from currency translation of approximately 7% adjust.
Adjusted EPS of <unk> 84.
It was up 27% versus the prior year, despite ongoing inflation and supply chain related headwinds.
Touching on pricing for a moment as we have been talking about through the last several quarters. Our efforts aimed at offsetting increased input costs have been one of our main focus areas.
While we have made significant progress in achieving the appropriate levels of price across most of our customer base in some areas. We have more work to do.
Moving to the operational and supply chain side the challenges we've been facing throughout the year continue.
However in fourth quarter, we began to see some areas of stabilization, including pockets of commodity costs leveling, albeit at high levels and a slight easing of global logistics and labor pressures.
With that we have started to move back to re localizing, our manufacturing and capitalizing on a region for region strategy.
Aided by these dynamics, we are seeing some reductions on our late backlogs and improvements in our fill rates.
While encouraging we view these recent trends as fragile and are cautiously optimistic regarding their sustainability.
In fourth quarter, we continued to lay the foundation for our future growth pursuing organic and inorganic opportunities to ensure we remain the leader in technology led filtration.
In June we announced the acquisition of <unk>, another Pearl and our string of Pearls life Sciences strategy aimed at creating a comprehensive solution offering across the upstream and downstream bio processing value chain for biopharmaceutical and food and beverage products.
<unk> novel membrane chromatography technology platform, which provides advantages over traditional resin and bead chromatography, along with our membrane expertise global sales and manufacturing footprint will allow donaldson to bring a broad portfolio of purification tools to the market.
<unk> for a wide range of biologics.
I am excited to welcome the <unk> team to Donaldson and look forward to reporting on our progress in the future now I will provide some segment context on our fourth quarter sales total company sales were $890 million up 15% from last year and engine total sales were $620 million.
Up about 18% sales in off road of $108 million were up 21% with growth in all major regions driven by continued high levels of equipment production and significant growth in our exhaust and emissions business in Europe .
On road sales of $35 million were up 5% from the prior year, excluding currency sales were up in all major regions with the exception of Asia Pacific where general market weakness continues to weigh on results.
Overall on road growth was positive in the quarter as we began lapping the discontinuation of some directed by equipment to a large OEM customer in North America.
That said supply chain challenges, including chip shortages are improving more modestly in this segment and limiting growth.
In engine aftermarket sales were $442 million, an increase of 18%.
Both the OE and independent channels were up double digits.
Proprietary product performance continues to be a very important driver and fourth quarter aftermarket sales of power core were up 30% year over year in line with performance in the third quarter.
On the independent side of engine aftermarket, we continue to build our presence and see encouraging growth rates in underpenetrated markets, such as Mexico and Brazil.
In aerospace and defense sales of $35 million were up 21% year over year with strength in replacement parts as we continue to benefit from the recovering commercial aerospace industry and market share gains.
Moving onto industrial a comment on our engine business in China.
<unk> engine sales were down 6% versus the prior year and down 2% in constant currency.
Overall market weakness, including that stemming from the COVID-19, Lockdowns, which resulted in plant closures for two weeks in the quarter negatively impacted results.
While our business in China will certainly continue to be impacted by the overall market trends I remain optimistic and excited about our future growth prospects in country, and we remain committed to growing share.
Now turning to the industrial segment.
Industrial sales increased 10% to $270 million sales of industrial filtration solutions or Iff's grew 14% to $196 million, mainly driven by industrial dust collection, new equipment and replacement parts.
Our process filtration business also delivered robust sales benefiting from new program wins.
This business hit an important milestone for the full year delivering approximately $100 million in sales, excluding the impact from currency translation.
Fourth quarter sales of gas turbine systems, or GTS were approximately $34 million.
Reflecting a 39% increase bolstered by the timing of replacement part sales in EMEA.
Sales of special applications were $40 million down 17% as the COVID-19 shutdowns in China continued to dampen disk drive sales.
Importantly, our venting products sales, which fall within special applications were up as customers expand the use of our high tech events for batteries and powertrains in the auto industry. This is a key strategic area for Donaldson given the opportunities that lie ahead in this rapidly expanding market.
<unk>.
In conclusion, our fourth quarter sales and earnings were a high watermark in the company's history and I look forward to carrying that underlying momentum forward into fiscal 2023.
Although there are many puts and takes as we think about our outlook for 2023, which Scott will discuss in a minute. We are forecasting another year of record revenue and record earnings in.
Importantly, we are also expecting year over year gross margin expansion.
In addition to our full year operating margin, which is forecasted to be a multi decade high now I will turn it over to Scott for more details on the financials and our outlook for fiscal 'twenty three Scott.
Thanks, Todd Good morning, everyone I want to start by thanking our Donaldson employees around the globe I am impressed with how our teams came together and once again delivered a solid year.
I am also excited about what is yet to come as we look to fiscal 2023.
Before talking through the details on fiscal 2023, I'll add some color to fourth quarter results by.
My comments to follow will focus on adjusted or non-GAAP results, which exclude charges related to the termination of our operations in Russia. These.
These charges totaled $3 4 million pre tax and include write offs for outstanding receivables and customer specific inventory.
Also included a restructuring charges related to the closing of our office in Russia.
To summarize the quarter.
Sales grew 15%.
Operating income was up approximately 19% and EPS of <unk> 84 increased 27% year over year.
Operating margin of 14, 9% was up 40 basis points versus prior year as operating expense leverage outweighed gross margin pressure.
Gross margin of 32, 9% improved 140 basis points sequentially. However, this represents a 150 basis point decline versus prior year.
While our pricing is now offsetting more persistent inflation such as that of commodities and freight other mark transition hurry factors, such as inefficiencies labor turnover and training costs as well as sales mix dampen margins.
Operating expenses as a percent of sales was 18.0% favorable by almost 200 basis points over prior year, driven primarily by leverage on higher sales.
I'll now briefly talk about fourth quarter segment profitability.
For the first time this fiscal year engine pre tax profit margin at 16, 6% was up 90 basis points year over year as our pricing efforts throughout the year began to offset cost pressure in the segment.
On the industrial side.
Pre tax profit margin was 17, 8% up 50 basis points versus prior year rebounding from a year over year decline in the third quarter. As a reminder, our three fiscal 2022 acquisitions Soliris pace and <unk> fall into this segment.
The integration of these three businesses is going well, we are continuing to invest in their growth and look forward to seeing them scale.
Now turning to the balance sheet and cash flow statements.
Our free cash flow this quarter was pressured by elevated working capital primarily driven by higher receivables from increased sales inventory, while still elevated was less of a story in the quarter.
We have begun to see some sequential stabilization in the global supply chain and continue to work towards increased efficiency.
Fourth quarter capital expenditures were 28 million, mainly driven by investments in capacity expansion, particularly in North America.
Cash conversion in the quarter was approximately 80% versus about 40% through the first nine months of the year. As we are now beginning to return to more normalized levels of conversion, resulting from inventory leveling.
In terms of capital deployment, we paid about $20 million on the <unk> acquisition and returned $45 million to shareholders with 28 million in the form of dividends and $17 million in share repurchases.
Our balance sheet remains in great shape, as we closed the year with a net debt to EBITDA ratio of 0.8 times.
The strength of our balance sheet combined with ample liquidity will allow us to continue pursuing our strategic objectives in 2023 and beyond.
Now I'll walk through our fiscal 'twenty three outlook.
Beginning with sales.
We expect our fiscal 2023 sales to be up within a range of between one and 5%.
Which includes a negative impact from currency translation of about 4%.
The currency impact in both engine and industrial is expected to be similar.
Also included in our sales guidance is a pricing benefit of about 6%.
I'll add some color on pricing and sales in fiscal 2022, the pricing impact in the second half of the year was twice what it was in the first half as actions taken throughout the year layered in.
Therefore, our 2023 pricing benefits will decrease as we begin to lap the prior year's actions, resulting in stronger gains earlier in the year.
Our engine, we expect a revenue increase of between zero and 4% driven.
Driven by growth in aftermarket and aerospace and defense.
We are forecasting mid single digit growth in both of these businesses, while lapping strong fiscal 2022 results.
In engine aftermarket robust demand driven by continued high levels of vehicle utilization and market share gains in less mature geographies are expected to contribute to growth.
Aerospace and defense sales are expected to be supported by the strengthening commercial aerospace industry, which still has plenty of runway and remains below pre COVID-19 levels.
For off road and on road sales are forecasted to be down low single digits due in part to the strategic exiting of certain low margin programs in both businesses as we think about the company's profitability and customer portfolio management, we are committed to focusing on higher margin opportunities that better.
It really affect the value, we bring to customers and are becoming more selective in the projects we engage in.
While this might have a short term negative impact on sales. We believe this is the right strategy for increasing profit on increasing sales over time.
A few other factors driving our expectations in these two businesses are.
And off road, our exhaust and emissions business is forecasting to slow as volumes related to new emissions programs are believed to have peaked in fiscal 2022, not returning to a more normal run rate.
But then on road sales will likely be range bound due to continued supply chain issues, including chip shortages.
Now I'll walk through the industrial segment, where we expect sales growth of 327% led by strength in ISS.
<unk> sales are projected to increase high single digits, driven by continued dust collection and process filtration product demand and contributions from our three fiscal 2022 acquisition.
GTS sales are projected to increase low single digits year over year.
<unk> applications growth is forecasted to be flat versus the prior year.
APAC market weakness is expected to continue to impact sales, including disk drive sales, which will likely still be pressured through the first half of the year.
Now I'll move on to our margin outlook, we are forecasting an operating margin range between 14, 5% and 15, 1% up from 13, 5% in fiscal 2022.
Operating margin is expected to be stronger in the second half of the year driven by gross margin expansion and operating expense leverage as we move through fiscal 2023 expense discipline will be critical for the company as we manage through a potential recessionary environment, but also strategically invest for the future.
Moving to EPS, we expect a range between $2 91.
And $3 seven.
Which at the midpoint represents an approximate 11% increase versus fiscal 2022.
Now onto our balance sheet and cash flow outlook as we work towards increased inventory efficiency, we expect working capital to be a source of cash.
Driving cash conversion in the range of between 110% on 125%.
A higher than historical average year.
Capital expenditures weighted towards our long term growth initiatives are forecasted to be between $115 million and $135 million, including investments in tooling and equipment for new products and technology maintenance and infrastructure investments capacity expansion and <unk>.
Continuous improvement projects for safety quality and margin improvement.
As we think about our capital deployment framework for fiscal 2023, our priorities have not changed.
We are committed to maintaining our disciplined and strategic approach to M&A with a focus on expanding and life Sciences markets.
As well as returning capital to shareholders through dividends and share repurchases.
Now I'll turn the call back to Todd.
Thanks Scott.
As we embark on the new fiscal year, I am optimistic and confident in the company's path forward.
The opportunities that lie ahead, both within our current core businesses and in our newer less mature, but higher margin businesses are abundant and we have the talent capabilities and resources to capitalize on them pushing Donaldson to the next stage of its evolution in fiscal 2023, our investments in our customers our people.
And our communities will continue.
With all of that said I would be remiss, if I did not touch on the recessionary concerns that are top of mind for all of us at Donaldson over our long history, we have been well positioned to withstand economic downturns and recessions have come out on the other side and our playbook approach is proven.
First cement our position as the leader in technology led filtration by meeting customer demand as we work down our backlogs and inventory utilizing our global and growing footprint to circumvent any supply chain issues.
Second capitalize on our more resilient businesses, such as our replacement parts businesses and growth areas, such as process filtration and our high tech events for batteries and powertrains.
Third judiciously manage costs to ensure our expense space aligns with our topline results.
Fourth utilize our strong balance sheet, which allows us to invest even in an economic downturn to pursue key opportunities in strategically important areas such as our advance and accelerate businesses in the life Sciences sector.
In closing while there is once again a lot of uncertainty heading into the fiscal year, we feel well prepared for what lies ahead and look forward to improving the company's profitability profile and adding another year of record sales and record earnings to the long history of Donaldson.
Our team showed tremendous resilience in fiscal 2022, and our agility will be a key asset in fiscal 2023.
Now I'll turn the call back to the operator to open the line for questions.
Thank you if you would like to ask a question. Please press star followed by the number one on your telephone keypad to withdraw your question. Please press star one again.
Our first question comes from Bryan Blair from Oppenheimer. Please go ahead. Your line is open.
Thank you good morning, everyone.
Turning.
I was hoping you could.
Our sales force, what you're contemplating in terms of first versus second half volume and <unk>.
23 sales guidance.
This impact is reasonably straightforward in terms of the carryover and cadence throughout the year, you've called out potential recessionary impact in that.
That must be factored in in some regard I guess to be direct or are you assuming that volume goes negative in the back half it was that.
In your current guidance.
Hey, Bryan good morning.
So we try to take all available factors into our guidance for the year.
When coming up with the overall sales number certainly because of the.
Covid situation, we're going to be lapping.
Some easy easier comps in the first half of the year.
So our sales growth will be much much stronger than the first half or the second half, but if you look at the half.
Combined we would have growth in bolthouse, although most of it in the first half of the year.
Okay I appreciate the color.
Just to level set what was the growth of your advanced accelerate portfolio in fiscal <unk> and the full year and if you have the metric on hand.
Where did advanced and accelerated shakeout as a percentage of total revenue for the year.
Sure, Brian I'll take that one so in the fourth quarter advance and accelerate with up 18%.
Year over year for about 60% of the total business.
Okay.
For the fourth quarter.
Okay. Thank you.
Hi curious if.
The.
Macro uncertainty that you cited and everyone is.
Clearly focused on.
Whether that has impacted your <unk>.
Deal funnel in terms of pursuing life science.
Assets, whether in terms of action ability or.
Perhaps positively with regard to seller expectations.
Bringing forward some activity.
Perhaps more more reasonable pricing.
Yes, we would say that overall, our M&A pipeline still remains strong it's very strategic and pointed in nature.
That valuations have come down slightly within the last quarter. However.
Talking about filtration companies and we're talking about life sciences. So both of them clearly are.
Above industrial averages, where we're where we're targeting so we have to be careful with that when we say has come down slightly still.
We view our efforts as being very strong and look forward to continued success as we completed three acquisitions in this fiscal year and we will continue to execute our overall the inorganic portion of our strategy.
Understood. Thank you again.
Our next question comes from Laurence Alexander from Jefferies. Please go ahead. Your line is open.
Hi, It's Dan Rizzo on for Laurence Thank you for taking my questions.
You mentioned, the backlog and where it is now I was just wondering.
To provide color where it is now versus what is the historical average how much higher it is or and what you expect over the next 12 months.
Sure, we would say actually.
The channel inventories out there have improved slightly.
Our overall late backlog is down slightly however, our backlog remains strong and our late backlog, although slightly improved still remains at uncomfortable levels and so our backlogs continue to be.
Quite nice.
And then you mentioned the Lockdowns in China, which are obvious, but I was wondering as we're coming out of that.
Are things, meaning expectations or is there kind of more of a I guess more of a gradual recovery than we probably would've been expected say two months ago or is it going according to plan.
Sure.
Yes.
Great question.
We're a bit more guarded there.
As we as we contemplate the outlook for China in and know what we feel we know we have certainly baked into the guidance, but but I would tell you relative to China.
We would we would clearly be a bit more conservative and based upon the nature of what we have been experiencing there in country.
If we think about the aftermarket business during during a recession like if you look back at like 2008 or you don't.
The industrial slowdown and I think in 2016 or whatever it was.
If the market falls or at least.
Volumes anyway drove this still remains somewhat positive.
Overall vehicle utilization across the world right now still remains very positive and very very heavy so we would tell you the aftermarket.
Growth opportunities are still prevalent.
From just overall utilization and end market strength, but also Donaldson has.
Underrepresented geographies, where we have additional growth opportunities that we continue to pursue and we look to have success over the over the quarters ahead.
Alright, Thank you very much.
Yes.
Our next question comes from John coming from Morgan Stanley . Please go ahead. Your line is open.
Hey, good morning, guys. Thanks for the question I just wanted to put maybe a finer point around the original kind of revenue question that was asked first obviously the guidance does imply that volumes are down for the year. If you kind of back out the pricing and the FX headwinds that you guys mentioned.
I guess with your response to that just be that Youre still kind of embedding a general level of conservatism, maybe that's reflective of some of those product lines.
Product line exits.
In the engine segment or do you feel like Youre actually seeing that materialize in the order books I guess from my perspective. It feels like you are still sounding pretty bullish tone on the overall end market backdrop. So just curious about negative implied volume guidance is actually reflected in your kind of order trends to date.
Sure. If you look at the engine are we what we're what we're looking at about the OEM sectors as U S up rest of the world more moderated, but we have a couple of headwinds there roughly a little bit more than 1%, where we have done some product management, we walked away from some business, but also on our exhaust and emissions business we.
We will see a decline there because last year, we had the benefits of some pre buys so you get about a little bit more than 1% based upon.
Those choices from Donaldson company.
And then rest of the world.
Actually you really start to feel it over in Japan, where you have some volume moderation, but very heavy FX hit.
And in Europe , where you have some volume moderation and also a very heavy FX hit. So you couple all of those factors.
Into the engine OE side of our business and.
That's how you get the more careful based guide and I do want to stress that we are being careful relative to the outlook in China as well.
Okay, Yes that makes sense. Thanks, Todd and then maybe just switching over to Europe for a second I'm. Just curious what you guys are seeing in terms of production footprint over there I mean, obviously the situation is still pretty volatile, but just curious that's kind of impacting your ability to produce or if you kind of factor in the level of cost inflation on that side of your portfolio in fiscal 'twenty three.
So as you as you look really across our aftermarket side there again.
We will not have Russia based revenue year over year, so that'll be a headwind.
In the neighborhood of 1% or so.
So as you look to Europe , please take that into consideration, but overall, we would say that Europe is doing okay. They're bouncing along surely there is a bit more moderation some carefulness going on but the business still remains very strong very positive.
Sure.
We haven't really seen signs of strong pullbacks or anything like that on incoming order activities et cetera.
We would say, it's probably just a little bit more careful at this point in time, and we continue to really keep a keen eye on it.
Okay. That's helpful. And then just last one for me in terms of the 6% pricing that you guys guided to I guess would you kind of characterize that is just reflective of the carryover that you've had from kind of pricing actions to date or is there kind of still scope for you to kind of go out there in the market, particularly within the independent channel maybe you could put out some further pricing actions as the year progresses.
Yes, the Illinois. This is Scott So we said 6% for the year. The majority of that relates from carryover from all the prices that we've layered in this year, which will obviously have a bigger impact in the first half than in the back half.
We're still going to go out with our typical.
Standard increases that we would normally doing on each year, we still have continuing labor cost increases and other cost increases we're going to have to deal with but the majority of it would be from this year with a few limited actions next year that will also contribute yes, I would say just basically that we've returned in the.
Independent aftermarket channel, we've returned back to a more normal like behavior.
And showed inflation kind of stay where it is at the at the current levels, we would expect to behave that way through the forward looking here.
Okay got it thanks for the time.
Our next question comes from Brian Drab from William Blair. Please go ahead. Your line is open.
Hi, Thanks, I just wanted to clarify on the revenue growth for the year. So when you said a second ago, Todd that Russia is a 1% impact us on a consolidated basis right.
Yes, so yes, absolutely and I remember overall, it's 2% as you look to prior years in the company, but last year.
It's closer to 1% because we had taken on some revenue prior to the conflict.
In eastern Europe taken place.
Okay. So in terms of year over year impact in fiscal 'twenty three.
It's about a one point headwind.
Headwind, yes, okay.
Okay got it so when we when we take the guidance of 1% to 5% in price FX is in that two <unk>.
Volume has been down one to the range of negative one to positive three so ex Russia that ranges.
Is basically zero to four.
Yes.
Okay got it, yes, which okay, which segment is that impacting more Russia I know, we talked about some of the food and beverage work that youre doing.
We are doing in Russia are continue to and are winding down is it more of an impact on the industrial side.
Engine.
And so it was definitely engine engine aftermarket.
Okay.
Okay.
Is that true that you have you have some in the industrial side of that on food and beverage and you mentioned some baby food processing et cetera is that just more much.
Minor relative to what Youre doing with engine.
Right. We did have some on the industrial side within food and beverage yes.
But it's largely an engine sorry.
Okay and if you.
The revenue I don't know that <unk>.
Been able to give us revenue for all the acquisitions precisely but.
Is that revenue.
Material or immaterial to revenue for <unk>.
Growth for 2023.
It's relatively immaterial.
I mean, it's less than 20 million Scott.
Can you give us any ballpark.
All three of them.
It's in that range.
Okay.
Alright, and then the last question was just guesses.
Yeah.
Youre talking about strategically moving away from some lower margin business and a couple of years ago you had the.
Operating margin target.
I guess, we're already beyond the three year for which you gave that target of 15 to 15, 8%.
I'm just curious if like that 15, 8% high.
High end of the range potentially goes up over the longer term.
As you.
Move away from this low margin business.
So we got to 14, 9% this quarter, which is just within a hair of 15%, which.
Would have been a great number of a $14 nine is still a solid improvement.
We expect to increase that again next year.
Yeah.
With our guidance of 14 five to 15, one so for the year, we expect to continue to improve the operating margin and we're committed to higher levels of profitability on higher sales. We have to continue to leverage the company invest in higher margin projects that mix the company up and continued to operate in.
<unk> and so we're going to continue to push the bounds of our operating margin horizon, because we feel as we continue to grow the company, we can leverage our opex and bring in higher than average margin opportunities. So.
We do expect to have an investor day next spring.
And we're working on planning that now are we'd like to invite you to alter the beautiful Bloomington, Minnesota and CR, our headquarters and we'll have more to say about that then.
Just the last question on that though.
Did you contemplate moving away from the low margin business.
It was April of 2019, when you showed that slide or is that.
No.
<unk> to the strategy since then.
No Brian we had that in 2019 in and actually some of it was in flight. It's not it's not an easy pivot when you walk away from some of the businesses, especially on the OE based that we've been talking about so those are those are multiple quarter based projects. When we when we ended up doing that with our with our customer base.
Got it okay. Thanks very much.
As a reminder to ask a question. Please press star followed by the number one.
Our next question comes from Rob Mason from Baird. Please go ahead. Your line is open.
Yes, good morning.
Good morning to you speak to that.
Could you just speak to what your expectations are around the advance and accelerate.
Portfolio.
For 'twenty three realm.
Relative to your 1% to 5%.
Overall sales done.
Yes, I mean, we continue to want to invest in our advance and accelerate portfolio that currently represented 62%.
The company and when we think about our investments we're always asking ourselves are we how we drive our investments to the right portion of our strategy into the rate portion of our company.
Certainly.
Our opportunity is there are going to drive our revenue growth. This year was.
Probably a little bit unusual with.
30% growth local currency in the fourth quarter and off road.
Almost 30%.
In local currency for the full year. So we had some really strong growth in certain pieces of our portfolio, but longer term our growth will be driven by our advance and accelerate portfolio and you can see from our guidance.
Guidance in off road and on road.
Al.
You can see that coming through this year.
Yes.
Just on that point.
You have the number of what the exhaust and emissions contributed to off road.
This past year.
Say, 29% overall.
Between three and 4% of total company revenue.
Okay. Okay.
Also just you spoke about the moderation and some raw material prices.
Sort of built into the gross margin expectation gross profit expectations for the year in terms of.
Raw materials with that.
Actually be a still a year over year headwind.
Or does that provide any relief.
I mean, we would expect relatively consistent.
Levels of cost this year in our committed to adjusting our prices if certain cost continue to spike or something.
Happen that would drive an unusual cost increase.
We're planning for relatively consistent commodity pricing this year.
Our gross margin analysis.
Okay.
Sure.
Just last question.
Pure logics the acquisition that was completed during the quarter.
Just curious I understand that small and its early stage, but how should we be thinking about that business.
Ramping over the next few years.
Specifically I'm curious if you would.
You've done your due diligence there.
Identified areas Theyre already specced into either vaccine therapeutics.
Success.
May have in clinical trials I'm, just curious what kind of visibility you have on that on that business.
Sure so.
It brings in a differentiated membrane chromatography technology to the company. So if you think overall at the media is that Donaldson users. We are very good and strong it at membrane based activities and so this allows their technology and our membrane experience to really combine and go.
Forward, they have patents as well as some.
Important trade secret formulations that all have been proven out in our laboratories prior to the acquisition.
They really focus on cutting edge applications such as.
There'll be there'll be applicable in mrna and peed, DNA and ion exchange and other affinity based separation opportunities.
Are already working with over 15 biopharmaceutical manufacturing companies.
And so while this is a bit of a longer cycle opportunity because they are pre revenue.
Donaldson strength of the balance sheet will certainly be able to help leverage that company forward and really we look forward to two.
Really great growth over over the years ahead.
Great.
I appreciate it.
Our last question comes from Nathan Jones from Stifel. Please go ahead. Your line is open.
Yes.
Good morning. This is Adam Farley on for Nathan I wanted to follow up on the strategic exiting lower margin programs and on and off road.
I'll just.
This exit is complete or should we expect this to be an ongoing process with maybe more to come in 'twenty three.
The one that we've been talking about.
For the past four quarters that one is complete we've lapped that now.
With the reporting of the fourth.
Fourth quarter, but obviously it did have considerable headwind in the year.
So that is.
Behind Us However, we continue to look at our portfolio, particularly in light of the inflationary pressures that we felt throughout the balance of the year.
And so that's just standard work for us now.
And we will continue to.
Take a look at low margin based products and frankly, if we're not getting paid for our technology.
We have choices to make and so that should we just consider that standard work looking forward.
Okay.
Okay, and then turning to Capex, our Capex was stepping back up to the $115 million to $135 million range.
Can you provide some color on where youre deploying that capital organically.
Maybe are some of these capex related items related to projects from 2022 that maybe got delayed.
Due to supply chain.
Yes.
Yes, I mean, so like you said, we had 115 to 135 million, we're certainly coming off.
Our lower year, there was certainly some delays in our Capex I think we ended up.
Having some delays that pushed some things from this year into next year. If we think overall about our capex for next year, we would say, it's kind of 75% growth 25% maintenance.
Growth with Tom in terms of bulk <unk>.
<unk>.
And new products.
We feel like those are good investments they have good overall returns for the company.
And help us should help us continue to.
We maintain a very strong return on invested capital.
Okay. Thank you for taking my questions. Thank.
Thank you.
We have no further questions I'd like to turn the call back over to Tod Carpenter for closing remarks.
That concludes today's call I'd like to thank everyone, who participated and I look forward to reporting our first quarter results. In late November also look forward to hosting all of you in the spring at the investors day that we will be holding with more information to come.
Regarding that have a great day goodbye.
This concludes today's conference call. Thank you for your participation you may now disconnect.
[music].